Objective: a-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. a-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing interest in studying both normal function and pathophysiology of a-cells. However, tools to target gene ablation or activation specifically of a-cells have been limited, compared to those available for b-cells. Previous Glucagon-Cre and Glucagon-CreER transgenic mouse lines have suffered from transgene silencing, and the only available Glucagon-CreER "knock-in" mouse line results in glucagon haploinsufficiency, which can confound the interpretation of gene deletion analyses. Therefore, we sought to develop a Glucagon-CreER T2 mouse line that would maintain normal glucagon expression and would be less susceptible to transgene silencing. Methods: We utilized CRISPR-Cas9 technology to insert an IRES-CreER T2 sequence into the 3 0 UTR of the Glucagon (Gcg) locus in mouse embryonic stem cells (ESCs). Targeted ESC clones were then injected into mouse blastocysts to obtain Gcg-CreER T2 mice. Recombination efficiency in GCG þ pancreatic a-cells and glucagon-like peptide 1 positive (GLP1 þ ) enteroendocrine L-cells was measured in Gcg-CreER-T2 ;Rosa26-LSL-YFP mice injected with tamoxifen during fetal development and adulthood. Results: Tamoxifen injection of Gcg-CreER T2 ;Rosa26-LSL-YFP mice induced high recombination efficiency of the Rosa26-LSL-YFP locus in perinatal and adult a-cells (88% and 95%, respectively), as well as in first-wave fetal a-cells (36%) and adult enteroendocrine L-cells (33%).
INTRODUCTION
Pancreatic a-cells secrete glucagon to increase plasma glucose levels in times of fasting and in opposition to insulin action [1] . a-cells make up 9e31% of the endocrine cells within murine islets of Langerhans, while the composition of human islets is much more variable than that of rodents, and the a-cell fraction of human islet endocrine cells can range from 10 to 65% [2] . It is now evident that a-cell dysfunction contributes to dysglycemia in type 1 and type 2 diabetes mellitus. Hyperglucagonemia exacerbates fasting and post-prandial hyperglycemia in type 2 diabetes [3e5], while patients with type 1 diabetes exhibit inappropriately low glucagon levels during hypoglycemia [6] but inappropriately elevated glucagon levels during hyperglycemia [3] , leading to broad and unpredictable glucose fluctuations. At present, the underlying etiologies of a-cell dysfunction in these disorders are unclear but do not seem to be completely attributable to insulin deficiency or resistance. Thus, the fields of diabetes and islet biology research could benefit from further specific investigation of a-cell physiology and pathophysiology. Additionally, several studies have shown that a-cells can transdifferentiate into b-cells [7e9] , and there is much interest in targeting a-cells to directly stimulate such transdifferentiation as a means of generating new b-cells for diabetes therapy. 1 Currently, there are few mouse models available with which to genetically modify a-cells in order to specifically study this cell population, and most of these mouse models are less effective than initially thought. The first Glucagon-Cre transgenic mouse line for acell specific gene ablation of loxP-flanked gene targets was generated in 2000. This randomly inserted transgene contained a 1.6 kb region of the rat Glucagon promoter and was initially reported to have a recombination efficiency in a-cells of 100% [10] . A later report in 2009 demonstrated only 85% recombination in a-cells [11] . Since then, multiple colonies of these Glucagon-Cre transgenic mice distributed to different labs have shown only 30e45% a-cell recombination, which is often insufficient to uncover the physiologic consequences of gene ablation, as the majority of a-cells still contain the wild type version of the gene of interest [12e14] . In 2013, a Glucagon-CreER T2 gene replacement mouse line was developed but demonstrated only 50e70% recombination efficiency in a-cells, which we confirmed (data not shown). However, a significant disadvantage of this Glucagon-CreER T2 mouse line is that the gene targeting design replaced the endogenous preproglucagon coding sequence with the CreER T2 cDNA, thus making these mice haploinsufficient for preproglucagon, confounding the analysis of gene deletions on a-cell function. In addition to pancreatic a-cells, the Preproglucagon transcript is also expressed in the L-cells of the intestine. L-cells are a subtype of enteroendocrine cells that share a common developmental transcriptional pattern with a-cells [15, 16] and are located within the epithelial lining of the small intestine and colon. In contrast to a-cells, which utilize prohormone convertase 2 to process Preproglucagon into Glucagon, the L-cells utilize prohormone convertases 1 and 3 to generate Glucagon-like peptide 1 (GLP1), GLP2, Oxyntomodulin, and Glicentin [17, 18] . GLP1 has many beneficial effects on b-cells and is thus a well-known diabetes therapeutic target. Interestingly, there is some evidence that a-cells and L-cells can alter their expression of prohormone convertase type, resulting in GLP1 production by a-cells or Glucagon production by L-cells. Thus, there is much interest in better understanding and harnessing L-cell biology. Here, we describe a novel Glucagon-CreER T2 gene-addition mouse line that was generated via CRISPR-Cas9 assisted gene targeting, does not disrupt glucagon expression from the targeted allele, and recapitulates endogenous glucagon and GLP1 expression. This will be a useful tool for the scientific community to perform specific genetic manipulations in murine a-cells and enteroendocrine L-cells.
MATERIALS AND METHODS

Cloning
The 5 0 homology arm (1,044 bp mapping to chr2:62,474,721e 62,475,764 on the mm10 build of the mouse genome, including part of exon 5, all of intron 5 and exon 6, and part of the 3 0 untranslated region (UTR) of the Gcg locus) and the 3 0 homology arm (1,039 bp mapping to chr2:62,473,652e62,474,690, including part of the 3 0 UTR of the Gcg locus and distal intergenic sequence) were PCR-amplified from mouse genomic DNA using the Phusion high-fidelity DNA polymerase (New England Biolabs, Ipswich, MA, USA). IRES and CreER T2 sequences were PCR-amplified from existing plasmids. See Supplemental Table 1 for PCR primers. The In-Fusion HD Cloning Kit (Clontech, Mountain View, CA, USA) was used to sub-clone the PCR-amplified sequences into the pBS vector (Stratagene, La Jolla, CA, USA) that was linearized with XmaI and EcoRI, to generate the gene targeting vector. A guide RNA (gRNA) targeting the ATTATCGCAGTCACAACACC sequence in the Gcg 3 0 UTR was cloned into the pX335 vector containing Cas9, following the CRISPR Genome Engineering Toolbox Target Sequence Cloning Protocol (http://www.genome-engineering.org/crispr/).
ESC targeting
Mouse V6.5 embryonic stem cells (ESCs; C57BL/6 and 129/sv F1 hybrid) were co-electroporated with the linearized pBS-based repair template vector, the pX335-sgRNA vector, and the Oct4-eGFP-PGKPuroR plasmid [19] . Transient transfectants were selected with 2 mg/ mL puromycin for 72 h. 192 clones were expanded and genotyped using primers to detect the 5 0 and 3 0 targeted sites (Supplemental Table 1 ), which confirmed proper targeting of seven clones. These clones were karyotyped, and two of the clones with the highest percentage of cells with normal karyotype were injected into pseudopregnant C57BL/6 female mice, resulting in two and eight chimeric pups, respectively. The chimeric mice were mated to C57BL/6 mice to obtain germline transmission of the Gcg-CreER T2 gene-addition allele.
Mice
Genotyping for Gcg-CreER T2 and Rosa26-LSL-YFP was performed using GoTaq Green Master Mix (Promega, Madison, WI, USA) with the primers and PCR conditions listed in Supplemental Table 2 . Heterozygous Gcg-CreER T2 mice were mated to homozygous Rosa26-LSL-YFP mice on the C57BL/6 background (The Jackson Laboratory, Bar Harbor, ME, USA, strain #006148) to obtain Gcg-CreER T2 ;Rosa26-LSL-YFP mice. 2e3 month old male and female Gcg-CreER T2 ;Rosa26-LSL-YFP mice were injected intraperitoneally with 100 mg/g body weight of tamoxifen (SigmaeAldrich, St. Louis, MO, USA, catalog #T5648) in corn oil (20 mg/mL), once daily for 3 consecutive days. Mice injected with or without tamoxifen were housed separately. The mice were killed 2 days, 7 days, or 1 month after the final injection. For the analysis of gene ablation efficacy during fetal development, adult male heterozygous Gcg-CreER T2 mice were mated to female homozygous Rosa26-LSL-YFP mice, and the mice were separated when a vaginal plug was observed (embryonic day [e] 0.5). Pregnant females were injected with 100 mg of tamoxifen at e9.5, e13.5, or e18.5, then 2 days later the embryos or pups (postnatal day [P] 1) were killed, and the intestinal tracts including pancreata were harvested. All mouse protocols were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.
Immunofluorescence staining
Tissues were fixed with 4% paraformaldehyde (PFA) at 4 C overnight (adult) or for 1 h (embryonic, postnatal), then rinsed in phosphatebuffered saline (PBS), and either dehydrated for paraffin embedding or immersed in 30% sucrose overnight at 4 C and embedded in optimum cutting temperature compound (OCT), then frozen for cryosectioning. Paraffin sections underwent antigen retrieval with R Buffer A (Electron Microscopy Sciences, Hatfield, PA, USA) in a pressure cooker (PickCell Laboratories, Agoura Hills, CA) for 1 h. Cre immunolabeling required cryosections. Sections were blocked with CASBlock (ThermoFisher, Waltham, MA, USA). Primary antibodies including goat anti-GFP (1:200, Abcam ab6673 lot 142576), rabbit anti-glucagon (1:200, Santa Cruz sc-13091), guinea pig anti-insulin (1:500, Invitrogen 180067), and rabbit anti-Cre (1:10,000, Millipore 69050-3) were incubated with the sections overnight at 4 C. After washing, donkey Cy2-, Cy3-, and Cy5-conjugated secondary antibodies (1:250e1:500, Jackson ImmunoResearch Laboratories) were incubated with sections at room temperature for 3 h. Sections were then incubated with DAPI (4 0 ,6-diamidino-2-phenylindole) for 1 min at room temperature to counterstain DNA prior to mounting with coverslips. Images were obtained using a Nikon Eclipse 80i widefield microscope. The anti-GFP antibody cross-reacts with YFP, and the anti-glucagon antibody cross-reacts with GLP1.
Islet isolation and fluorescence-activated cell sorting (FACS)
Islets from adult Gcg-CreER T2 ;Rosa26-LSL-YFP mice at 3e4 months of age that had been injected with tamoxifen (n ¼ 4) or without (n ¼ 3) were isolated by collagenase digestion of pancreatic tissue followed by hand-picking, as previously described [20, 21] , yielding 800 and 500 islets per group, respectively. The islets were immediately dissociated with 0.05% trypsin for 3 min at 37 C, and the reaction was quenched with fetal bovine serum (FBS). Dissociated islet cells were incubated with Aqua Live/Dead (ThermoFisher, Waltham, MA, USA) per manufacturer's instructions, then fixed with 1% PFA for 10 min at room temperature, and quenched with 3 mM glycine. Cells were then incubated with goat anti-GFP and rabbit anti-glucagon primary antibodies at 1:200 dilution followed by donkey Cy2-conjugated anti-goat and Cy5-conjugated anti-rabbit secondary antibodies at 1:500 dilution, both steps in blocking buffer (1% BSA, 0.1% saponin, 1X PBS) for 20 min at room temperature. Cells were sorted using FACSAria II (BD Biosciences, San Jose, CA, USA).
2.6. Plasma glucagon measurements Adult mice at 2e4 months of age were fasted overnight for 16 h, then anesthetized using continuous isoflurane inhalation. Plasma glucose was measured from the tail tip using a Breeze 2 glucometer (Bayer, Mishawaka, IN, USA). Whole blood was then collected by cardiac puncture and transferred to heparinized tubes (Sarstedt, Nümbrecht, Germany), which were temporarily stored on ice, then centrifuged at 2,000Âg for 5 min at 4 C, and the plasma supernatant was stored at À20 C. Plasma glucagon levels were measured using the Glucagon ELISA e 10 mL kit (Mercodia, Uppsala, Sweden), following the manufacturer's instructions and using technical duplicates. Original Article 2.7. Pancreas harvest for RT-qPCR and protein Whole pancreas was collected from adult mice after overnight fast as described above, then immediately immersed in 15 mL TRIzol Reagent (ThermoFisher, Waltham, MA, USA), homogenized, snap-frozen in liquid nitrogen, and stored at À80 C. RNA was later extracted from the aqueous phase per manufacturer's instructions using 0.2X chloroform, followed by isopropanol precipitation. RNA quality and concentration were analyzed with the RNA 6000 Nano kit (Agilent, Santa Clara, CA, USA). cDNA was synthesized from 1 mg of total RNA using SuperScript II Reverse Transcriptase (ThermoFisher, Waltham, MA, USA). qPCR was performed using the intron-spanning primers listed in Supplemental Table 3 and 2X Brilliant III SYBR Green QPCR Master Mix (Agilent, Santa Clara, CA, USA), with technical triplicates. DNA and protein were extracted from the organic phase of the Trizol homogenate, per manufacturer's instructions, with modified protein resuspension based on [22] . Total protein content was measured using the Bio-Rad Protein Assay standard procedure for microtiter plates (Bio-Rad, Hercules, CA, USA) using technical triplicates. Pancreatic glucagon content was measured using the Glucagon ELISA e 10 mL kit (Mercodia, Uppsala, Sweden), following the manufacturer's instructions and using technical duplicates.
2.8. Statistical analyses Prism 6.0 (GraphPad Software, La Jolla, CA, USA) was used to make graphs and perform statistical analyses. RT-qPCR and ELISA results were analyzed using one-way ANOVA with Tukey's multiple comparisons test with a single pooled variance.
RESULTS
Gcg-CreER T2 expression Mice with germline transmission of IRES-CreER
T2 inserted in the 3 0 UTR of the Gcg locus were derived from targeted mouse ESCs electroporated with vectors containing Cas9 nuclease with a gRNA designed to target the 3 0 UTR of the Gcg allele, and a repair template containing the IRES-CreER T2 sequence flanked by 5 0 and 3 0 arms homologous to the Gcg locus ( Figure 1A ; for details see Materials and methods section). Pancreata from adult Gcg-CreER T2 mice showed Cre expression exclusively in a-cells ( Figure 1B ).
3.2.
Gcg-CreER T2 recombination efficiency Adult Gcg-CreER T2 ;Rosa-LSL-YFP mice injected with tamoxifen and killed 7 days later exhibited YFP expression, indicative of CreER T2 -mediated recombination of the Rosa-LSL-YFP locus, in 92% of GCGpositive pancreatic a-cells by histology (Figure 2A and D) and 95% by FACS ( Figure 2E ). YFP was also expressed in 31% of enteroendocrine L-cells in the small intestine ( Figure 2B and D) , and 37% of enteroendocrine L-cells in the colon (Figure 2C and D) , respectively, by histology. A similar percentage of YFP þ /GLP1 þ cells were observed in the small intestine and colon of adult mice killed 2 days after the final tamoxifen injection (data not shown). YFP was very rarely identified in GCG-negative cells in islets (Figure 2A and E) . However, some YFP þ / GLP1 À cells were observed in the intestine.
Furthermore, YFP expression persisted in 95% of pancreatic a-cells of adult Gcg-CreER T2 ;Rosa-LSL-YFP mice killed 1 month after tamoxifen injection ( Figure 3A and B) , consistent with the low turnover rate of these cells. In contrast, no enteroendocrine L-cells were found to express YFP 1 month after tamoxifen injection ( Figure 3B ), because enteroendocrine cells, like goblet cells and enterocytes, are replaced by new cells originating from intestinal crypts every three to five days, and because tamoxifen disappeared from the circulation. To evaluate CreER T2 -mediated recombination efficiency during pancreas development, pregnant female mice were injected with tamoxifen at different embryonic stages. Expression of YFP was observed in 36% of first-wave GCG þ cells at e11.5 after low-dose tamoxifen injection at e9.5 ( Figure 4A and E). Recombination was observed in 46% of early second-wave GCG þ cells at e15.5 after tamoxifen injection at e13.5 ( Figure 4B and E), and in 88% of GCG þ cells at P1 after tamoxifen injection at e18.5 ( Figure 4C and E). Among these time points, YFP and GLP1 expression were first identified in the intestine at P1, with a high percentage of YFP þ /GLP1 þ cells ( Figure 4D , n ¼ 5). Notably, Gcg-CreER T2 ;Rosa-LSL-YFP mice exhibited some "leaky" recombination in the absence of tamoxifen, with 0e13% of adult acells expressing YFP without injection of tamoxifen by histology ( Figure 5A and B) and an average of 7% by FACS ( Figure 2E ). There was no YFP expression observed in the intestine of Gcg-CreER T2 ;Rosa-LSL-YFP mice not injected with tamoxifen ( Figure 5B ) nor in pancreata from Rosa-LSL-YFP mice injected with tamoxifen ( Figure 5C , n ¼ 4). No YFP expression was detected in the midbrain (data not shown).
Glucagon expression
Gcg-CreER T2 heterozygous and homozygous mice were healthy and exhibited comparable fasting plasma glucagon levels as wild type littermates ( Figure 6A ). Likewise, Gcg mRNA and GCG protein levels in total pancreas homogenates were not significantly different in Gcg- CreER T2 heterozygous and homozygous mice compared to wild type littermate controls ( Figure 6B and C) . Thus, there is no indication of a deleterious effect of the Gcg-CreER T2 gene-addition allele described above.
DISCUSSION
Here, we derived an improved mouse model for conditional and inducible genetic manipulation in preproglucagon-expressing cell lin- The low level of Rosa-LSL-YFP recombination that was observed in acells in the absence of tamoxifen is similar to that described in other CreER T2 mouse models, including Pdx1-CreER mice [23, 24] . This leaky expression is likely due to a combination of high expression of CreER T2 from the preproglucagon locus, as well as the particularly easilyrecombined nature of the Rosa locus in comparison to other loci. Using CRISPR-Cas9 assisted homology-directed recombination, we inserted an IRES-CreER T2 sequence into the 3 0 UTR of the Gcg locus in murine ESCs without disrupting the Gcg coding exons, allowing for coexpression of GCG and CreER T2 . Because this mouse model utilizes the endogenous Gcg promoter to drive expression of CreER T2 , expression of CreER T2 mirrors that of the endogenous preproglucagon gene, even at early developmental time points. Furthermore, CreER T2 expression in this mouse model is less likely to be silenced than in previous transgenic mouse models, as it is located in the native gene context.
CONCLUSIONS
We generated a new and improved Gcg-CreER T2 mouse line that expresses CreER T2 from the endogenous preproglucagon locus without disrupting preproglucagon expression. This mouse line exhibits high recombination efficiency in pancreatic a-cells and enteroendocrine Lcells without disrupting preproglucagon gene expression. We expect that because the CreER T2 gene utilizes an endogenous promoter, rather than a transgenic promoter, its expression will be less susceptible to gene silencing, as has affected other Gcg-CreER mouse lines. In summary, these Gcg-CreER T2 mice can be used to temporally manipulate genetics specifically in pancreatic a-cells and enteroendocrine L-cells.
CONTRIBUTIONS
AMA designed experiments, collected data, analyzed data, drafted the article, revised the article, and approved the final version for publication. JZ conceived the study, designed experiments, revised the article, and approved the final version for publication. AH designed experiments and approved the final version for publication. AB collected and analyzed data and approved the final version for publication. KHK conceived the study, designed experiments, revised the article, and approved the final version for publication. Values were normalized to total pancreatic protein. Error bars represent standard deviation.
